Pesquisar
Incyte Corp
INCYAdicionar à lista de desejos
119.470USD
-3.520-2.86%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
23.89BValor de mercado
16.37P/L TTM
Mais detalhes de Incyte Corp Empresa
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Informações de Incyte Corp
Código da empresaINCY
Nome da EmpresaIncyte Corp
Data de listagemDec 06, 1993
CEOMeury (Bill)
Número de funcionários2617
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 06
Endereço1801 Augustine Cut-Off
CidadeWILMINGTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19803
Telefone13024986700
Sitehttps://www.incyte.com/
Código da empresaINCY
Data de listagemDec 06, 1993
CEOMeury (Bill)
Executivos da empresa Incyte Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.06M
-34.96%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
358.08K
+22.15%
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
143.78K
+1.32%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
142.57K
+1.15%
Dr. Pablo J. Cagnoni
Dr. Pablo J. Cagnoni
President - Research and Development
President - Research and Development
81.09K
-11.74%
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
76.94K
+2.13%
Mr. Thomas R. Tray
Mr. Thomas R. Tray
Vice President - Finance and Chief Accounting Officer, (Principal Accounting Officer), Principal Financial Officer
Vice President - Finance and Chief Accounting Officer, (Principal Accounting Officer), Principal Financial Officer
69.46K
+0.82%
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
60.95K
+2.69%
Dr. Susanne Schaffert, Ph.D.
Dr. Susanne Schaffert, Ph.D.
Independent Director
Independent Director
47.17K
+19.54%
Mr. Lee Heeson
Mr. Lee Heeson
Executive Vice President - Incyte, International
Executive Vice President - Incyte, International
38.04K
-0.29%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.06M
-34.96%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
358.08K
+22.15%
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
143.78K
+1.32%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
142.57K
+1.15%
Dr. Pablo J. Cagnoni
Dr. Pablo J. Cagnoni
President - Research and Development
President - Research and Development
81.09K
-11.74%
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
76.94K
+2.13%
Perguntas frequentes
Quem são os cinco principais acionistas de Incyte Corp?
Os cinco principais acionistas de Incyte Corp são: Mr. Herve Hoppenot
Quantas instituições possuem ações da Incyte Corp (INCY)?
Em 2026Q1, 1617 instituições possuíam ações da Incyte Corp, com valor de mercado aproximado de 209.33M, representando 104.84% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -3757856.00.
Qual é a maior fonte de receita da Incyte Corp?
Em 2026Q1, o segmento de negócios JAKAFI revenues gerou a maior receita para Incyte Corp, totalizando 3.09B e representando 60.15% da receita total.